Malaysian Applied Biology Journal

  • Increase font size
  • Default font size
  • Decrease font size


E-mail Print PDF

Malays. Appl. Biol. (2014) 43(2): 35-40



1Discipline of Surgery (School of Medicine) and North Queensland Centre for Cancer Research (Australian Institute of Tropical Medicine), James Cook University, Townsville, Queensland 4811, Australia.

2 Discipline of Pathology, Queensland Health & Pathology Scientific Services, Gold Coast Hospital and Griffith Medical School, Gold Coast, Queensland 4215, Australia.


Present address: Department of Chemical Science (Biochemistry), Faculty of Science, Universiti Tunku Abdul Rahman, Kampar, Perak 31900, Malaysia.

E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it


Colorectal cancer develops in a multi-step process and is associated with genetic alterations. Blocking apoptosis is a key factor to unlimited cell proliferation and immortalization. Survivin expression inhibits the programmed cell death process, apoptosis. This molecule could play a potential role in cancer development. Survivin is an attractive target for clinical trials to develop cancer treatment. RNA was prepared from colorectal tumor and adjacent non-tumor tissues and then transcribed to complementary DNA. Human survivin mRNA levels were quantitatively measured by real time polymerase chain reaction (PCR) in tumor and adjacent non-tumor tissues. Expression levels of survivin mRNA in adenocarcinomas were significantly higher than in non-tumor mucosa (p < 0.0001). The expressions of survivin mRNA in adenocarcinomas were related to the degree of differentiation (survivin; p=0.034). No difference was found with other clinicopathological features. These findings indicate survivin role in colorectal carcinogenesis. Survivin could be used as a potential diagnostic and prognostic marker in colorectal cancer. Successful inhibition of this molecule could lead to the development of a new drug for cancer therapy.


Survivin, Colorectal cancer, Real time PCR


Adida, C., Berrebi, D., Peuchmaur, M., Reyes-Mugica, M. & Altieri, D.C. 1998. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet, 351: 882-883.
Altieri, D.C. 2001. The molecular bases and potential role of survivin in cancer diagnosis      and therapy. Trends in Molecular Medicine, 7: 542-547.

Ambrosini, G., Adida, C. & Altieri, D,C. 1997. A novel anti-apoptosis gene, survivin,
expressed in cancer and lymphoma. Nature Medicine, 3: 917-921.

Atikcan, S., Unsal, E., Demirag, F., Koksal, D. & Yilmaz, A. 2006. Correlation between     survivin
expression and prognosis in non-small cell lung cancer. Respiratory Medicine, 100: 2220-2226.

Bustin, S.A. 2000. Absolute quantification of mRNA using real-time reverse
transcription polymerase chain reaction assays. Journal of Molecular Endocrinology, 25: 169-193.

De Kok, J.B., Ruers, T.J., Van Muijen, G.N., Van Bokhoven, A., Willems, H.L. & Swinkels, D.W. 2000. Real-Time quantification of human telomerase reverse transcriptase     mRNA in tumors and healthy tissues. Clinical Chemistry, 46: 313-318.

Endoh, T., Tsuji, N., Asanuma, K., Yagihashi, A. & Watanabe, N. 2005. Survivin enhances telomerase activity via up-regulation of specificity protein 1- and c-Myc- mediated human telomerase reverse transcriptase gene transcription. Experimental Cell Research, 305: 300-311.

Gianani, R., Jarboe, E., Orlicky, D., Frost, M., Bobak, J., Lehner, R. & Shroyer, K.R. 2001. Expression of survivin in normal, hyperplastic and neoplastic colonic           mucosa. Human Pathology, 32:119-125.

Kami, K., Doi, R., Koizumi, M., Toyoda, E. & Mori, T., Ito, D., Fujimoto, K., Wada, M., Miyatake, S. & Imamura, M . 2004. Survivin expression is a prognostic marker in pancreatic cancer patients. Surgery, 136: 443-448.

Kawasaki, H., Altieri, D.C., Lu, C.D., Toyoda, M., Tenjo, T. & Tanigawa, N. 1998. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Research, 58: 5071-5074.
Kawasaki, H., Toyoda, M., Shinohara, H., Okuda, J., Watanabe, I., Yamamoto, T., Tanaka, K., Tenjo, T. & Tamigawa, N. 2001. Expression         of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer, 91: 2026-2032.

Meng, H., Lu, C., Mabuchi, H. & Tanigawa, N. 2004. Prognostic significance and different properties of survivin splicing variants in gastric cancer. Cancer Letter, 216: 147-155.

Sah, N.K., Khan, Z., Khan, G.J. & Bisen, P.S. 2006. Structural, functional and therapeutic biology of survivin. Cancer Letter, 244: 164-171.

Sarela, A.I., Scott, N., Ramsdale, J., Markham, A.F. & Guillou, P.J. 2001. Immunohistochemical detection of the anti-apoptosis protein, survivin, predicts survival after curative resection of stage II colorectal carcinomas. Annals of Surgical Oncology, 8: 305-310.

Sarela, A.I., Macadam, R.C.A., Farmery, S.M., Markham, A.F. & Guillou, P.J. 2000. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut, 46: 645-650.

Sohn, D.M., Kim, S.Y., Baek, M.J., Lim, C.W., Lee, M.H., Cho, M.S. & Kim, T.Y. 2006. Expression of survivin and clinical correlation in patients with breast cancer. Biomedicine & Pharmacotherapy, 60: 289-292.

Span, P.N., Sweep, F.C., Wiegerinck, E.T., Tjan-Heijnen, V.C., Manders, P., Beex, L.V. & De Kok, J.B. 2004. Survivin is an independent prognostic marker for risk     stratification of breast cancer patients. Clinical Chemistry, 50: 1986-1993.

Vogelstein, B. & Kinzler, K.W. 1993. The multistep nature of cancer. Trends in Genetics, 9: 138-141.
Vogt, P.K. 1993. Cancer genes. Western Journal of Medicine, 158: 273-278.

Zhang, T., Otevrel, T., Gao, Z., Ehrlich, S.M., Fields, J.Z. & Boman, B.M. 2001. Evidence that APC regulates survivin expression: A possible mechanism contributing to the         stem cell original of colorectal cancer. Cancer Research, 62: 8664-8667.


Main Menu